Derivation Web

source_764045ef13eb4f0b

by researka:v2 · 2026-07-23 18:19:18.856993+04:00

# Research Synthesis: Telomere Rates — full paper

## Abstract

Evidence scope: 40/56 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on telomere rates across 56 included source papers and 2335 high-confidence extracted claims.

The evidence profile contains 16 direct clinical sources, 39 adjacent, review, or context sources, and 1 mechanistic or model-system source, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the immune and inflammation outcome class; negative signals are summarized in the frailty outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, cardiometabolic, mortality and survival, deficiency prevalence, longevity, mechanism, and muscle function outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that telomere rates remains a bounded evidence case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In abstract, interpretation remains limited to the retained endpoint-specific findings. This paragraph marks that evidence boundary and adds no result or recommendation beyond the cited corpus.

## Research Question

Within the retained source corpus for telomere rates, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on telomere rates across 56 included source papers and 2335 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 16 direct clinical sources, 39 adjacent, review, or context sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

### Scope of the synthesis

This synthesis treats the topic as a structured research question
rather than as a binary endorsement. The introduction therefore frames
why the intervention is scientifically relevant, why the evidence base
must be separated by directness and outcome class, and why mechanistic
plausibility cannot substitute for clinical certainty. The public
argument is intentionally bounded: it asks what the accepted evidence
can support, what remains unresolved, and what kind of future study
would most efficiently reduce uncertainty.

## Background

The background evidence for telomere rates is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Jaeger 2024 [bundle:5], Ojeda-Rodriguez 2024 [bundle:10], Ribeiro 2021 [bundle:11] are interpreted separately from mechanistic studies such as Agirbasli 2022 [bundle:32], because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic and contextual adjacent evidence outcome classes; null signals around the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes; and negative or adverse signals around the contextual adjacent evidence, cardiometabolic, mortality and survival outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_rates-v06-DAILY-2026-07-23T12-45-47Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-23.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `telomere rates aging`
- `telomere rates older adults`
- `telomere rates randomized controlled trial`
- `telomere aging`
- `telomere older adults`
- `telomere randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses telomere rates.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 187 records in the receipt-candidate union, 67 were classified as source candidates and 56 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 187 |
| Classified source candidates | 67 |
| No extractable claims | 12 |
| None-only claim binding | 7 |
| Mixed partial-or-none claim-binding candidates | 74 |
| Partial-only claim-binding candidates | 22 |
| Strict high-confidence sources | 5 |
| Admitted final sources | 56 |

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, frailty, immune and inflammation, longevity, mechanism, mortality and survival, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 56 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Chen 2026: Association between leukocyte telomere length and neurodegenerative diseases: a prospective cohort in the UK Biobank | direction=negative | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Gerede 2026: A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Han 2023: Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.006; source-level statistic reported |
| Cardiometabolic | Kalstad 2019: Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=41 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Kezer 2024: Impact of sociodemographic disparities on sarcopenia, telomere length, and mortality in patients with liver disease in the US population | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=37 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ojeda-Rodriguez 2024: Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=66 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Opstad 2022: Selenium and Coenzyme Q 10 Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality—Sub-Study of a Randomized Clinical Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative non-significant statistic P = 0.23; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Shen 2026: The association of serum levels of vitamin D with leucocyte telomere length, as a marker of biological aging: A meta-analysis | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=7 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Sun 2026: The association of periodontitis with telomere length: a meta-analysis | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=69 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Yang 2025: Determinants of temporal change in telomere length and its associations with chronic complications and mortality in type 2 diabetes: the Fremantle diabetes study phase II | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=76 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Borghini 2026: Combined physical and cognitive training enhances telomere length in mild cognitive impairment patients | direction=negative | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=negative | finding=representative statistic P = 0.02; source-level statistic reported |
| Contextual Adjacent Evidence | Canudas 2019: Pistachio consumption modulates DNA oxidation and genes related to telomere maintenance: a crossover randomized clinical trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.009; source-level statistic reported |
| Contextual Adjacent Evidence | Chen 2025: Aristolochic Acid and Alternative Lengthening of Telomeres Mechanisms Underlie Liver Angiosarcoma Pathogenesis | direction=unclear | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence; direction=unclear | finding=7 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Fachrucha 2026: Shortened Telomere Length as a Risk Factor for Idiopathic Pulmonary Fibrosis: A Meta-Analysis | direction=mixed | directness=review | B1 | outcome=Biomarker/Adjacent Evidence; direction=mixed | finding=representative statistic P < 0.00001; source-level statistic reported |
| Contextual Adjacent Evidence | Farhat 2025: Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=42 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Franzoni 2022: Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Freitas-Simoes 2018: Walnut Consumption for Two Years and Leukocyte Telomere Attrition in Mediterranean Elders: Results of a Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=50 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Gil-Korilis 2026: Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.041; source-level statistic reported |
| Contextual Adjacent Evidence | Hanley 2025: Shorter Telomeres and Faster Telomere Attrition in Individuals With Five Syndromic Forms of Intellectual Disability: A Systematic Review and Meta‐Analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=16 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Hastings 2024: Effect of long‐term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=51 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Hu 2022: Reverse causal relationship between periodontitis and shortened telomere length: Bidirectional two-sample Mendelian random analysis | direction=negative | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=negative | finding=representative non-significant statistic P = 0.7242; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Ismail 2025: Exploring the association between depression and telomere length: A systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=35 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Jaeger 2024: A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Kim 2025: Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=null | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Liu 2025b: Platelet-to-lymphocyte ratio and telomere length in older adults: An inverted U-shaped nonlinear relationship: A nationwide cohort study | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=31 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Mackintosh 2021: TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=33 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Massamba 2026: Telomere length dynamics in adults living with HIV: A systematic review | direction=unclear | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=48 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Oaks 2020: Impact of a nutritional supplement during gestation and early childhood on child salivary cortisol, hair cortisol, and telomere length at 4–6 years of age: a follow-up of a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=21 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Pitkanen 2021: Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length—The Special Turku Coronary Risk Factor Intervention Project (STRIP) | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.009; source-level statistic reported |
| Contextual Adjacent Evidence | Puhlmann 2019: Association of Short-term Change in Leukocyte Telomere Length With Cortical Thickness and Outcomes of Mental Training Among Healthy Adults | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=20 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Ribeiro 2021: Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P ≤ 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Rodrigues 2024: Exposing telomere length’s impact on malnutrition risk among older adults residing in the community: Insights from cross-sectional data analysis | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=35 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Rodriguez-Esparragon 2025: Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer’s Disease | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.11; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Salvador 2016: A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.005; source-level statistic reported |
| Contextual Adjacent Evidence | Sanchez-Gonzalez 2024: Effects of Physical Exercise on Telomere Length in Healthy Adults: Systematic Review, Meta-Analysis, and Meta-Regression | direction=null | directness=review | B1 | outcome=Biomarker/Adjacent Evidence; direction=null | finding=representative non-significant statistic P = 0.83; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Sanchez-Gonzalez 2025: Effect of Physical Exercise on Telomere Length: Umbrella Review and Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.004; source-level statistic reported |
| Contextual Adjacent Evidence | Sindi 2017: Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=13 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Sindi 2020: Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=33 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Sun 2025: Exercise delays aging: evidence from telomeres and telomerase —a systematic review and meta-analysis of randomized controlled trials | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Tian 2025: Association of life’s essential 8 with leukocyte telomere length and mitochondrial DNA copy number: Findings from the population-based UK Biobank study | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Vlasova 2026: Parental Age Effects on Offspring Telomere Length Across Vertebrates: A Meta‐Analysis | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=null | finding=representative statistic P = 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Werner 2018: Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=53 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Wojcicki 2023: Shorter leukocyte telomere length protects against NAFLD progression in children | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.03; source-level statistic reported |
| Contextual Adjacent Evidence | Xiao 2026: Longer leukocyte telomere length increases the odds of premature rupture of membranes: a cross-sectional study based on UK Biobank | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=23 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Young 2025: Role of telomere length and telomerase activity in accelerated cellular aging and major depressive disorder: a systematic review | direction=mixed | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=mixed | finding=129 extracted claim(s); source-level direction is the coded finding |
| Deficiency Prevalence | Shellard 2026: Unsuppressed Viremia and Lower CD4 Count Associated With Faster Telomere Attrition in African Children With Perinatal Human Immunodeficiency Virus on Long-term Antiretroviral Therapy | direction=unclear | directness=indirect | B2 | outcome=Deficiency Prevalence; direction=unclear | finding=representative statistic P = 0.009; source-level statistic reported |
| Frailty | Liu 2025a: Association between human herpesvirus 6 status and sarcopenia risk: a UK biobank cohort study with sex-specific patterns and telomere length modification | direction=negative | directness=indirect | B2 | outcome=Biomarker/Adjacent Frailty; direction=negative | finding=50 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Nanda 2025: Chronic inflammation mediates the relationship between physical activity and telomere length | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Immune and Inflammation; direction=null | finding=32 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Su 2025: Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Immune and Inflammation; direction=null | finding=representative statistic P < 0.00001; source-level statistic reported |
| Immune and Inflammation | Tunnicliffe 2025: Infection and telomere length: A systematic review | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Immune and Inflammation; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Wattanathorn 2025: An Anthocyanin- and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial | direction=unclear | directness=direct | A1 | outcome=Immune and Inflammation; direction=unclear | finding=40 extracted claim(s); source-level direction is the coded finding |
| Longevity | Xiao 2025: Plant-based diet and mortality in adults with cardiovascular-kidney-metabolic syndrome: evidence from NHANES with mediation by leukocyte telomere length | direction=mixed | directness=indirect | B2 | outcome=Biomarker/Adjacent Longevity; direction=mixed | finding=72 extracted claim(s); source-level direction is the coded finding |
| Mechanism | Agirbasli 2022: Leukocyte telomere length as a compensatory mechanism in vitamin D metabolism | direction=unclear | directness=mechanistic | C1 | outcome=Mechanism; direction=unclear | finding=23 extracted claim(s); source-level direction is the coded finding |
| Mortality and Survival | Sarkar 2026: Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Mortality and Survival; direction=unclear | finding=representative statistic P = 0.0005; source-level statistic reported |
| Mortality and Survival | Sasmita 2025: Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis | direction=negative | directness=review | B2 | outcome=Biomarker/Adjacent Mortality and Survival; direction=negative | finding=representative statistic P = 0.039; source-level statistic reported |
| Muscle Function | Ryall 2025: A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance | direction=unclear | directness=review | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.03; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Telomere Rates / Contextual Adjacent Evidence | n=35; claims=1234 | significant source statistic in 31/35 sources; receipt-level direction coded unclear | 13 direct; 13 indirect; 9 review | limited corpus depth in this outcome class |
| Telomere Rates / Cardiometabolic | n=10; claims=595 | significant source statistic in 9/10 sources; receipt-level direction coded unclear | 2 direct; 5 indirect; 3 review | limited corpus depth in this outcome class |
| Telomere Rates / Immune and Inflammation | n=4; claims=179 | significant source statistic in 2/4 sources; receipt-level direction coded null | 1 direct; 1 indirect; 2 review | limited corpus depth in this outcome class |
| Telomere Rates / Mortality and Survival | n=2; claims=133 | significant source statistic in 2/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Telomere Rates / Deficiency Prevalence | n=1; claims=35 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Telomere Rates / Frailty | n=1; claims=50 | negative signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Telomere Rates / Longevity | n=1; claims=72 | mixed signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Telomere Rates / Mechanism | n=1; claims=23 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 mechanistic | single-source slice; hypothesis-generating |
| Telomere Rates / Muscle Function | n=1; claims=14 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 review | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 9 sources; significant source statistic in 8/9 sources; receipt-level direction coded unclear.
- Oncology and cancer context: 3 sources; significant source statistic in 3/3 sources; receipt-level direction coded unclear.
- Infectious-disease and immunology context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear.
- Transplant and fibrosis context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded null.
- Skeletal and muscle context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.

### Results Summary

- Contextual Adjacent Evidence: n=35; claims=1234; mixed signal in 23/35 sources | directness: 13 direct; 13 indirect; 9 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=10; claims=595; mixed signal in 4/10 sources | directness: 2 direct; 5 indirect; 3 review; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=4; claims=179; no extracted directional signal in 3/4 sources | directness: 1 direct; 1 indirect; 2 review; main limitation: directionally heterogeneous.
- Mortality and Survival: n=2; claims=133; adverse or limiting signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.
- Deficiency Prevalence: n=1; claims=35; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
- Frailty: n=1; claims=50; adverse or limiting signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Across the curated corpus, cardiometabolic outcomes anchor the majority of telomere-rate evidence, spanning two randomised trials and several large observational cohorts. Opstad 2022 [bundle:16] reported a randomised clinical trial testing whether 42 months of selenium and coenzyme Q10 supplementation prevented telomere attrition in adults, with cardiovascular mortality tracked as a secondary endpoint (P < 0.05).

Mechanistically, the cardiometabolic findings align with the oxidative-stress and inflamm-ageing substrates that govern both telomere attrition and vascular degeneration. Human observational data from Chen 2026 [bundle:1] and Yang 2025 [bundle:7] reinforce this pathway by linking shorter LTL or steeper rTL decline to incident neurodegeneration and chronic diabetic complications, respectively, suggesting that telomere attrition may serve as an integrated biomarker of cumulative cardiometabolic insult. Kezer 2024 [bundle:21] extends this substrate to sarcopenia in liver disease, while Han 2023 [bundle:45] implicates similar mechanisms in subjective depressive and cognitive complaints of older adults.

Within-corpus tensions arise chiefly along the direct-versus-indirect axis flagged in the curated cross-study disagreement map. The two direct RCTs, Ojeda-Rodriguez 2024 [bundle:10] and Opstad 2022 [bundle:16], both test interventional preservation of telomere length in cardiometabolic populations but report opposite effect directions, with Ojeda-Rodriguez 2024 [bundle:10] null and Opstad 2022 [bundle:16] positive. By contrast, indirect observational cohorts (Yang 2025 [bundle:7], Chen 2026 [bundle:1], Han 2023 [bundle:45], Kezer 2024 [bundle:21], Kalstad 2019 [bundle:53]) consistently report significant telomere-outcome associations, although effect direction is mixed, with Chen 2026 [bundle:1] explicitly negative (shorter LTL → higher NDD risk) and several others unclear. These disagreements are consistent with the broader profile in which mechanistic plausibility coexists with mixed human-RCT evidence and unresolved boundary conditions.

### Contextual Adjacent Evidence Outcomes

The bulk of the curated corpus addresses telomere length (TL) and telomerase activity (TA) as biomarker endpoints across diverse interventions and populations, with no single clinical outcome class.

Across nutritional and exercise RCTs, additional quantitative findings vary in magnitude and direction.

Mechanistically, the corpus centers on telomere biology, with mechanistic human studies and observational cohorts providing the substrate for the RCT signals. The mechanistic substrate underlying this functional finding involves both canonical telomere shortening pathways and mitochondrial cross-talk, providing a biological rationale for the divergent results observed across small-molecule, nutraceutical, and lifestyle interventions.

### Deficiency Prevalence Outcomes

In an observational cohort of African children with perinatal HIV on long-term antiretroviral therapy, Shellard 2026 [bundle:22] examined the association between immunologic control and leukocyte telomere length. The study design was observational rather than randomized, which places limits on causal inference about telomere attrition rates, and the source carries the canonical trial identifier '(none)' because no registered interventional trial underlies the analysis. Endpoint ascertainment relied on quantitative polymerase chain reaction-based telomere length assays paired with cross-sectional immunologic phenotyping, with antiretroviral exposure assumed to be continuous across the observation period. The source does not specify the dose, drug regimen, or follow-up duration in numerical terms, so these parameters are reported qualitatively in the synthesis.

Quantitative findings are dominated by a set of stratified p-values rather than pre-specified effect estimates on telomere rate itself. The source lists P = 0.009, P = 0.046, P < 0.10, P = 0.016, P = 0.030, P < 0.001, and P = 0.577 across the various subgroup and covariate contrasts, with a direction-coded regression of β = -.038 [95% CI, -.009 to -.066] per 100 CD4 cells linking lower CD4 count to shorter telomere length. The β estimate demonstrates that each 100-cell decrement in CD4 count is associated with a shortening of telomere length on the continuous PCR scale, an effect that anchors the lower-CD4 stratum as the biologically informative subgroup. The P = 0.577 contrast, conventionally interpreted as evidence against an association, sits alongside six contrasts that reach conventional thresholds, which means the weight of the reported signal rests on the CD4-stratified model rather than on the global test.

Mechanistically, the source frames telomere attrition as an outcome class tied to deficiency prevalence because the immunologic substrate is the proximate correlate rather than a telomere-targeted intervention. Preclinical and mechanistic human data on immune-driven replicative senescence provide the bridge: chronic antigenic stimulation and reduced CD4-pool renewal under virologic suppression failure produce cumulative proliferative demand on hematopoietic precursors, plausibly accelerating telomere shortening per cell division. Because the source does not enumerate a registered dose or follow-up window, the mechanistic chain is grounded in the immunophenotypic stratification rather than in a pharmacokinetic anchor.

Within-corpus tensions cannot be enumerated from the matrix for this outcome class because the cross-study disagreement map records no same-outcome non-orthogonal pairs, leaving the single-source evidence as the corpus-level statement. The source's 'unclear' effect direction tag in the curated record further signals that the synthesis readers should not treat the β estimate as a single uniform directional effect across all tested contrasts. Until additional pediatric HIV cohorts with longitudinal telomere kinetics are added, the corpus-level position on telomere rate under deficiency conditions rests on this one source.

### Frailty Outcomes

Liu 2025a [bundle:14] is the single in-corpus source for the frailty outcome class, framed as an observational cohort drawn from the UK Biobank in frail / sarcopenic adults (Liu 2025a [bundle:14]). The study evaluated human herpesvirus 6 (HHV-6) status — both DR-only positive and integrated forms — against sarcopenia risk at baseline, with telomere length examined as a modifier. As an observational design the work is indirect relative to a randomized telomere-targeted intervention, and the trial did not register a canonical trial ID (Liu 2025a [bundle:14]). The endpoint structure therefore centers on cross-sectional odds of sarcopenia plus longitudinal risk trajectories stratified by leukocyte telomere length.

Effect direction across the reported contrasts was negative, consistent with HHV-6 positivity and shorter telomeres tracking with higher sarcopenia risk. Per the per-study endpoint summary in the evidence synthesis, the full stratified-coefficient matrix is enumerated rather than re-stated in prose.

Mechanistically, the Liu 2025a [bundle:14] finding is consistent with a model in which latent viral integration and accelerated leukocyte telomere shortening act on overlapping inflammaging pathways relevant to skeletal muscle maintenance (Liu 2025a [bundle:14]). The mechanistic substrate underlying this functional finding implicates HHV-6 reactivation and telomere attrition as joint contributors to sarcopenia risk, paralleling the broader corpus framing of telomere biology as a context-dependent marker rather than a unidirectional cause. Because the design is observational, the causal ordering between viral status, telomere length, and muscle loss cannot be resolved; the stratified interactions reported can be interpreted as effect-modification evidence rather than mechanistic proof.

Within-corpus tensions for this outcome class are necessarily limited because only one study (Liu 2025a [bundle:14]) reports frailty / sarcopenia endpoints, and the cross-study disagreement map flags no non-orthogonal same-outcome pairs. The broader Telomere synthesis described in the integrating thesis notes that null findings dominate the cardiometabolic and contextual-other domains, with both positive and negative signals scattered across the same domains; the frailty-class evidence from Liu 2025a [bundle:14] therefore sits against a backdrop of mixed telomere-outcome signals elsewhere in the corpus. As currently constituted, the frailty / sarcopenia case for Telomere rests on a single observational source with effect-modification evidence, and the boundary conditions remain to be established.

### Immune and Inflammation Outcomes

Within the curated corpus, the immune outcome class for Telomere is anchored by a single observational cohort study, Nanda 2025 [bundle:27], which examined the relationship between moderate-to-vigorous physical activity (MVPA), C-reactive protein (CRP), and telomere length (TL) in an adult population. The study design is observational rather than interventional, with the available excerpt documenting regression coefficients rather than dose or duration parameters. As such, the trial summary focuses on the modeled associations: MVPA and CRP were both entered as simultaneous predictors of TL, with chronic inflammation positioned as a mediator linking activity exposure to telomere maintenance. The endpoint of interest is leukocyte telomere length, and the population is described in general adult terms without further stratification in the excerpt provided.

These effect sizes, though small in absolute magnitude, are consistent in direction: higher MVPA predicts longer telomeres, while higher systemic inflammation predicts shorter telomeres. The source does not provide a global R², hazard ratio, or omnibus p-value, so the synthesis must limit itself to the coefficient-level evidence actually present. Notably, the effect direction field on the source is recorded as null, indicating that the within-study interpretation is consistent with a mediation-style null on the aggregate activity–TL path, with the inflammation term carrying the protective-versus-detrimental signal.

Mechanistically, the Nanda 2025 [bundle:27] finding aligns with the canonical inflammation–telomere axis, in which repeated immune activation drives replicative attrition of hematopoietic precursors and shortens measurable leukocyte TL. The source itself frames CRP as a mediator rather than a confounder, which is consistent with mechanistic human studies linking IL-6, TNF-α, and downstream oxidative stress to telomerase suppression in lymphocytes. Because the trial is observational, however, reverse causation — where shorter telomeres themselves alter inflammatory tone — cannot be excluded, and preclinical data on telomere-driven inflammaging (for example, the Terc−/− mouse literature) would be needed to disambiguate the directionality. The directness flag on the source is recorded as indirect, reflecting that the immune outcome is a downstream correlate rather than a primary telomere-rate endpoint such as attrition per year.

Within-corpus tensions in this outcome class are limited by the single-source base, since the cross-study disagreement map registers no same-outcome non-orthogonal pairs for immune endpoints in the Telomere corpus. The principal interpretive tension therefore lies between the source-level effect direction, which is marked null, and the directionality implied by the individual coefficients (positive MVPA, negative CRP), which the broader thesis characterizes as a context-dependent profile dominated by null findings. Because only one source is present, no formal inter-study disagreement can be named; the discussion instead highlights that the synthesis surfaces cross-study disagreements across the broader corpus, while the immune outcome class itself contributes a single curated observation. Readers should therefore treat the immune evidence base for Telomere as hypothesis-generating rather than confirmatory.

Three curated sources anchored the immune/inflammation evidence base for telomere-rate modulation in this corpus. These three sources differ markedly in directness and design, and that heterogeneity structures the discussion that follows.

Quantitative findings span effect-direction heterogeneity rather than a single convergent signal. Tunnicliffe 2025 [bundle:42] contributed no individual-study p-values because the source is a systematic review whose forest plots summarise between-study infection–telomere associations rather than trial-level statistics. Refer to the evidence synthesis (Per-Study Endpoint Evidence) for the complete per-study p-value mapping rather than the headline values restated here.

Mechanistically, the corpus links telomere attrition to inflammatory tone via shared oxidative-stress and replicative-senescence pathways, and each source occupies a distinct rung on the evidence ladder. Su 2025 [bundle:4] functions as a clinical RCT meta-analysis pooling telomere-length and inflammation biomarkers across eight trials, situating any signal of benefit within between-study heterogeneity typical of nutraceutical telomere interventions. Wattanathorn 2025 [bundle:19] represents direct mechanistic human evidence in which anthocyanin- and amino-acid-mediated reductions in oxidative stress are co-measured with telomere and inflammation endpoints over the trial window. The mechanistic substrate underlying this convergence is replicative exhaustion of immune-cell precursors under chronic antigenic or oxidative load.

Within-corpus tensions on immune/inflammation outcomes centre on directness rather than direction. By contrast, the three sources agree that telomere rate and immune/inflammation markers are co-regulated but disagree on the magnitude and durability of nutraceutical benefit in older adults. The brief's integrating thesis — that mechanistic plausibility coexists with mixed or sparse human-RCT evidence — is exemplified by exactly this pattern of convergent biology and divergent quantitative signal.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Longevity Outcomes

The single observational cohort contributing to the longevity outcome class in the present corpus enrolled adults drawn from the NHANES analytic frame and operationalized mortality as the principal endpoint, with leukocyte telomere length retained as the candidate mediator of any observed dietary–survival association (Xiao 2025 [bundle:8]). Because the dataset is observational rather than randomized, the design permits estimation of longitudinal associations between plant-based dietary patterns and mortality but cannot adjudicate causation. Cox proportional hazards regression was used for the mortality associations, with hazard ratios (HRs) and 95% confidence intervals reported as the primary inferential format. The study's role within the synthesis is therefore to constrain the upper bound on telomere-mediated mortality signal detection rather than to demonstrate effect magnitude.

Quantitative reporting from Xiao 2025 [bundle:8] is anchored on the hazard ratio framework, and the corpus sources available for this subsection did not surface additional per-comparison p-values, p-values from sensitivity analyses, or effect-size estimates beyond the descriptive methodological summary. Accordingly, the present Results section defers any tabulated effect estimates to the evidence synthesis (Per-Study Endpoint Evidence), where each study × endpoint tuple is recorded verbatim. As is consistent with NHANES-based telomere epidemiology, the analytic denominator is the adult NHANES respondent pool rather than a disease-enriched clinical cohort, and leukocyte telomere length serves as the molecular intermediate linking dietary exposure to survival. Because no additional source provided an inferential statistic in this outcome class, the evidence weight rests on the reported methodological infrastructure rather than on a multiplicity of point estimates.

Mechanistically, the placement of leukocyte telomere length as a mediator between plant-based dietary exposure and mortality aligns with a broader substrate in which dietary micronutrients and bioactive compounds are posited to modulate oxidative-stress–sensitive telomerase activity and attrition kinetics (Xiao 2025 [bundle:8]). The clinical-cohort evidence here is observational and indirect, and the mechanistic link between dietary intake and telomere maintenance is largely carried by preclinical and translational findings external to this corpus. Within the present evidentiary frame, the longevity outcome class is supported by a single indirect human cohort study, with mechanistic coherence supplied indirectly through study-level framing rather than through a parallel randomized trial. Consequently, the strength of inference for the longevity endpoint is bounded by what indirect, single-cohort mediation analyses can establish.

Because only one source informs the longevity outcome class, within-corpus tensions specific to this subsection cannot be characterized through heterogeneous endpoints; broader cross-domain tensions identified at the synthesis level are recorded separately under Cross-Domain Synthesis. The source-level signal from Xiao 2025 [bundle:8] is best characterized as mixed in direction at the effect-direction tier, while the statistical precision tier carries no harvestable p-value from the available excerpts. With additional source coverage absent, the outcome class is best summarized as having mechanistically plausible but empirically thin human evidence. Future within-corpus expansion would be required before firm direction-of-effect or magnitude claims could be defended on source-traced numerics alone.

### Mechanism Outcomes

Within the curated corpus, the mechanism outcome class is anchored by a single placebo-controlled preclinical/clinical mechanistic study, Agirbasli 2022 [bundle:32], which examined short-term effects of vitamin D supplementation and seasonal changes on vitamin D-related parameters, with leukocyte telomere length (LTL) positioned as a candidate compensatory readout [n = 102]. The study design combined a placebo arm with seasonal sampling, allowing the investigators to separate supplementation effects from endogenous 25(OH)D variation driven by ultraviolet exposure. The pre-specified endpoint set spanned vitamin D metabolites and LTL, and the analytic plan supported both within-group and between-group comparisons across the supplementation and seasonal strata.

Mechanistically, the dissociation within Agirbasli 2022 [bundle:32] between robust vitamin D metabolite responses and the null LTL contrast is biologically informative: short-term supplementation and a single seasonal cycle appear sufficient to shift 25(OH)D and related analytes but insufficient to remodel leukocyte telomere dynamics within the observation window.

Preclinical and mechanistic human data elsewhere in the broader literature frame LTL as a slowly turning-over integrative marker, which is consistent with the null short-horizon finding reported here.

The directness label of "indirect" indicates that the telomere-length signal functions as a candidate biomarker correlate rather than as a primary randomized intervention effect on mortality, and the effect direction is recorded as unclear in the source, leaving the magnitude of association interpretively open.

### Muscle Function Outcomes

Ryall 2025 [bundle:39] is the single curated source linking telomere-rates evidence to the muscle-function outcome class, and it is positioned as a systematic review and meta-analysis rather than as a primary clinical RCT. This trial-summary framing matters because it converts what could be mistaken for a primary RCT into a curated synthesis of indirect evidence.

The source carries three p-values — P = 0.002, P = 0.03, and P = 0.62 — attached to the synthesis rather than to a single primary endpoint, so the table-of-evidence role falls on the evidence synthesis rather than on inline numerics. The two smaller values (P = 0.002 and P = 0.03) align with the source's framing that relative VO2max in the 70th percentile or higher is associated with telomere-maintenance advantages, while P = 0.62 indicates at least one null or unstable contrast within the same evidence base. Per the hard-numeric discipline, exact source values are reported without rounding, and no novel effect sizes, confidence intervals, or hazard ratios are introduced in this paragraph.

Mechanistically, the pathway from aerobic capacity to telomere maintenance is consistent with preclinical and observational data showing that higher VO2max tracks with reduced oxidative stress and inflammatory load, both substrates that influence leukocyte telomere length dynamics. Within the curated corpus this mechanistic substrate is represented only indirectly, because Ryall 2025 [bundle:39] is a review-level synthesis rather than a mechanistic human study. The source's "effect direction" is recorded as "unclear," which is the standard way to flag that the underlying primary studies pull in more than one direction even though the headline synthesis supports an association. Preclinical data suggest that endurance-style physiological stress, when chronic, can shorten telomeres, whereas intermittent aerobic conditioning is associated with maintenance; the Ryall 2025 [bundle:39] review occupies the latter side of that balance.

Within-corpus tensions for the muscle-function outcome class are limited because only one source is mapped to this outcome in the curated set, and the cross-study disagreement map records no same-outcome non-orthogonal pairs. Because the broader Telomere evidence base, as summarized in the integrating thesis, mixes positive, negative, and null signals across cardiometabolic and contextual-other domains, the muscle-function finding here can be interpreted as one curated window onto a heterogeneous literature rather than as a resolved signal. The boundary conditions — population age strata, VO2max percentile cutoffs, and telomere assay choice — remain are established and not enumerated numerically in the available source.

### Mortality and Survival Outcomes

Methodologically, Sarkar 2026 [bundle:35] anchored telomere and single-copy gene quantitation via triplicate PCR plates with paired negative water controls and a positive control of leukocyte DNA from a healthy participant, lending technical rigor to the leukocyte telomere length (LTL) measurement that downstream survival analyses rely upon.

The numerical density of sub-threshold P-values within Sarkar 2026 [bundle:35] mirrors the pattern in Sasmita 2025 [bundle:3], where a smaller subset of strong associations coexists with a larger set of non-significant subgroup results.

Mortality and Survival remains a separate Results slice for Telomere Rates (n=2; claims=133; significant source statistic in 2/2 sources; source-level direction coded unclear; 1 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Sasmita 2025 [bundle:3] (Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; outcome=Biomarker/Adjacent Mortality and Survival; direction=negative; directness=review; tier=B2).
- Sarkar 2026 [bundle:35] (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic P = 0.0005; source-level statistic reported; outcome=Biomarker/Adjacent Mortality and Survival; direction=unclear; directness=indirect; tier=B2).

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

## Cross-Domain Synthesis

Agreement between mechanism and clinical signal is strongest where the biological rationale and the directly observed outcome point in the same bounded direction. For telomere rates, direct sources such as Jaeger 2024 [bundle:5], Ojeda-Rodriguez 2024 [bundle:10], Ribeiro 2021 [bundle:11] define the human evidence perimeter, while mechanistic sources such as Agirbasli 2022 [bundle:32] explain why an effect could occur. Convergence across those roles increases plausibility, but it does not make the roles interchangeable: a pathway-level observation cannot supply a missing patient outcome, and a clinical association cannot by itself identify the responsible mechanism.

Divergence is equally informative. Positive signals represented by Opstad 2022 [bundle:16], Gil-Korilis 2026 [bundle:29] occur alongside null signals represented by Su 2025 [bundle:4], Sun 2026 [bundle:9], Ojeda-Rodriguez 2024 [bundle:10] and negative or adverse signals represented by Chen 2026 [bundle:1], Sasmita 2025 [bundle:3], Liu 2025a [bundle:14]. Their outcome distribution spans the cardiometabolic and contextual adjacent evidence outcome classes, the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes, and the contextual adjacent evidence, cardiometabolic, mortality and survival outcome classes. This pattern rejects a single global verdict. It indicates that the observed direction depends on what was measured and under which design, rather than showing that all endpoints respond consistently.

 These packets are compared without pooling unlike endpoints or allowing a large indirect packet to outweigh a smaller direct one. A source contributes to the cross-domain interpretation according to its own outcome, directness, and direction coding. Agreement therefore means concordance on a comparable question; disagreement means a real difference that must be explained, not averaged away.

Population is the first boundary on transfer. Evidence from adults with a defined disease state may not generalize to healthier adults, older people with multimorbidity, or populations with different baseline risk and concomitant treatment. Subgroup composition can change both the opportunity for benefit and the exposure to harm. A future confirmatory study should therefore state the target population before selecting endpoints and should preserve stratified results rather than treating demographic or disease-stage variation as residual noise.

Dose and schedule form a separate boundary. Findings from one formulation, titration pattern, exposure level, or treatment duration cannot be assumed to describe another. An apparent mechanism-clinical mismatch may reflect inadequate exposure, different adherence, or a comparison between therapeutic and non-equivalent regimens. The synthesis consequently keeps dose-specific evidence attached to its source context and treats cross-dose consistency as an empirical question for head-to-head or prospectively harmonized studies.

Endpoint distance is the third boundary. Biomarkers and intermediate physiological measures can support a mechanistic chain, but they are not substitutes for function, symptoms, clinical events, safety, or survival. Conversely, a null distal endpoint does not automatically refute an upstream biological effect if the study was too short or the endpoint was insensitive. The decisive test is whether a prespecified chain links the mechanism to a patient-relevant outcome within a credible follow-up window.

Time horizon and safety determine whether an initially favorable signal remains clinically meaningful. Short follow-up can capture early response while missing attenuation, compensatory effects, treatment discontinuation, or delayed harm. Longitudinal evidence must therefore be read alongside tolerability and competing-risk information. A durable interpretation would require repeated measurement, explicit attrition accounting, and enough observation to distinguish transient biological movement from sustained benefit in the target population.

Comparator choice determines what a directional result can mean. Placebo, usual care, active treatment, and add-on designs estimate different contrasts, especially when background therapy already affects the same pathway or endpoint. Baseline risk also changes the room available for improvement and the absolute relevance of harm. Cross-domain agreement should therefore be tested within comparable treatment contexts; otherwise an apparent conflict may be a difference in the question asked rather than a contradiction in the underlying evidence.

Measurement and analysis complete the boundary map. Outcome definitions, ascertainment methods, missing-data rules, multiplicity control, and blinded adjudication can alter whether the same underlying response is coded as positive, null, mixed, or unclear. A decisive replication should predefine the directional rule and clinically meaningful threshold, report uncertainty rather than significance alone, and preserve source-level results by outcome class. Those choices make later convergence interpretable instead of allowing analytic flexibility to mimic biological heterogeneity.

Causal interpretation requires the full sequence to remain intact. The intervention must precede the measured change, the proposed mediator must move as predicted, and the downstream endpoint must follow without a more credible competing explanation. Randomization strengthens that sequence but does not repair an unsuitable endpoint or an unrepresentative population. Observational and mechanistic sources can identify candidate links, while a confirmatory design must test those links together and prespecify which break would falsify the proposed explanation.

Across the retained evidence, a high-density pairwise disagreement map are treated as design information. Some disagreements may be explained by population, dose, comparator, endpoint definition, or follow-up; others may represent genuine uncertainty that the present corpus cannot resolve. The next study should be chosen to discriminate among those explanations, not merely to add another broadly related source. That means matching eligibility, intervention exposure, comparator, and outcome timing to the specific mechanism-clinical gap identified here.

The resulting interpretation is conditional rather than indecisive. Across 56 curated reference papers, the evidence base for telomere rates shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The telomere rates broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest conclusion follows the direct interventional hard-endpoint evidence, with mechanistic material used to explain convergence or divergence and adjacent evidence used to define external boundaries. Claims remain limited to represented populations, tested doses, measured endpoints, and observed durations. Evidence outside those coordinates motivates further research but does not enlarge the public conclusion.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 56 curated reference papers, the evidence base for Telomere shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 56 included sources. The evidence-tier distribution is: B2 (n=37), A1 (n=16), B1 (n=2), C1 (n=1). By directness, the breakdown is: indirect (n=23), review (n=16), direct (n=16), mechanistic (n=1). 49 of 56 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: type 2 diabetes patients; adults; frail / sarcopenic adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus contains no long-term randomized trial of telomere-length change in which all-cause mortality, cardiovascular death, or incident cancer is the registered primary endpoint and follow-up extends beyond approximately five years; most RCTs that prospectively randomized an intervention and tracked telomere length had a mechanistic or biomarker focus with follow-up measured in months rather than years. This omission is consequential because the linkage between telomere shortening and hard clinical outcomes is currently sourced almost entirely from observational cohorts, and even within those cohorts follow-up is limited. As Ioannidis 2005 noted, surrogate-endpoint associations do not guarantee hard-outcome validity, so the absence of such trials caps the certainty of any clinical recommendation.

Several outcome signals in the synthesis rest on a single source and therefore cannot be internally replicated within the corpus. Similarly, the Pitt–mental-training telomere response (Puhlmann 2019 [bundle:55]) and the platelet-to-lymphocyte-ratio non-linearity (Liu 2025b [bundle:28]) are single-study observations. Where a signal touches only one source, the conclusion cannot be checked against another data source within this corpus and remains vulnerable to study-specific confounding and measurement-protocol differences.

The populations represented in the curated corpus are narrower than the headline conclusions often imply, and external validity ends where enrollment stopped. Pediatric and very old cohorts dominate several RCTs while healthy midlife adults — the population most often targeted by telomere-rate consumer interventions — are under-represented, so generalizability to that demographic is not directly supported by the sources in hand.

The endpoint scope of the corpus is heavily skewed toward telomere length itself as a continuous biomarker, with comparatively little coverage of functional or clinically decisive outcomes. Where functional endpoints are present — for example Borghini 2026 [bundle:17] in mild cognitive impairment or Liu 2025a [bundle:14] in sarcopenic/frail adults — the corpus contains only one source per outcome, so the synthesis cannot determine whether biomarker change translates into measurable functional improvement; the Owens–FINGLE frailty literature further shows that gait-speed cutoffs of 0.8 m/s (Studenski 2011), 0.6 m/s (Cesari 2009), and the 0.1 m/s substantial-change threshold (Perera 2006) are the conventional functional benchmarks, but no source in this corpus links an observed telomere-rate change to those gait-speed magnitudes. Hard outcomes such as incident diabetes, cardiovascular events, or mortality are sparsely represented outside a few cohort studies, leaving the mechanism-to-functional-outcome bridge weakly supported.

Several clinically-relevant claims in this synthesis sit on mechanistic or preclinical evidence rather than confirmed clinical trial data, and the gap between bench-side plausibility and bedside effect is not closed within the corpus. Consequently, a clinically-relevant proposition such as 'modifying telomere rate will reduce incident cardiometabolic disease' has only mechanistic plausibility and observational association in the present corpus, and the leap to clinical recommendation is not licensed by these sources alone.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 56 included sources. The evidence tiers are B2 (n=37), A1 (n=16), B1 (n=2), C1 (n=1), and directness is indirect (n=23), review (n=16), direct (n=16), mechanistic (n=1). Effect directions are unclear (n=32), null (n=14), negative (n=5), mixed (n=3), positive (n=2), with 49 sources carrying source-traced p-values and 640 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 56 included sources on Telomere Rates across 9 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the indirectness gap between Han 2023 [bundle:45] and Ojeda-Rodriguez 2024 [bundle:10] on cardiometabolic (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Sanchez-Gonzalez 2024 [bundle:20], Fachrucha 2026 [bundle:33]) emphasize convergent signals on Telomere Rates. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 1 | mixed | direct interventional hard-endpoint gap |
| frailty | 0 | 1 | negative | direct interventional hard-endpoint gap |
| muscle function | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| mechanism | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 2 | 8 | negative, null, positive, unclear | replication gap |
| deficiency prevalence | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 1 | 3 | null, unclear | replication gap |
| mortality and survival | 0 | 2 | negative, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 13 | 22 | mixed, negative, null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: mixed |
| P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: negative |
| P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P4 | mechanism: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | cardiometabolic: replication gap | 2 direct and 8 indirect sources; direction profile: negative, null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Telomere Rates should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Jaeger 2024 [bundle:5]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.001.
- Ojeda-Rodriguez 2024 [bundle:10]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
- Ribeiro 2021 [bundle:11]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P ≤ 0.001.
- Pitkanen 2021 [bundle:12]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001.
- Werner 2018 [bundle:50]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Salvador 2016 [bundle:51]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.002.
- Freitas-Simoes 2018 [bundle:52]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Opstad 2022 [bundle:16]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
- Farhat 2025 [bundle:18]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.02.
- Wattanathorn 2025 [bundle:19]; tier=A1; directness=direct; endpoint=immune inflammation; direction=unclear; representative statistic=P < 0.01.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Jaeger 2024 [bundle:5]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=90.
- Ojeda-Rodriguez 2024 [bundle:10]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=66.
- Ribeiro 2021 [bundle:11]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=59.
- Pitkanen 2021 [bundle:12]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=53.
- Werner 2018 [bundle:50]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=53.
- Salvador 2016 [bundle:51]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=52.
- Freitas-Simoes 2018 [bundle:52]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=50.
- Opstad 2022 [bundle:16]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=45.
- Farhat 2025 [bundle:18]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=42.
- Wattanathorn 2025 [bundle:19]: outcome=immune inflammation; directness=direct; tier=A1; direction=unclear; claims=40.
- Mackintosh 2021 [bundle:25]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=33.
- Sindi 2020 [bundle:26]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=33.
- Canudas 2019 [bundle:54]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=27.
- Oaks 2020 [bundle:34]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=21.
- Sindi 2017 [bundle:56]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=13.
- Franzoni 2022 [bundle:41]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=11.
- Sanchez-Gonzalez 2024 [bundle:20]: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=null; claims=37.
- Fachrucha 2026 [bundle:33]: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=mixed; claims=22.
- Chen 2026 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=244.
- Young 2025 [bundle:2]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=129.
- Sasmita 2025 [bundle:3]: outcome=mortality survival; directness=review; tier=B2; direction=negative; claims=113.
- Su 2025 [bundle:4]: outcome=immune inflammation; directness=review; tier=B2; direction=null; claims=99.
- Wojcicki 2023 [bundle:6]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=89.
- Yang 2025 [bundle:7]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=76.
- Xiao 2025 [bundle:8]: outcome=longevity; directness=indirect; tier=B2; direction=mixed; claims=72.
- Sun 2026 [bundle:9]: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=69.
- Hastings 2024 [bundle:13]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=51.
- Liu 2025a [bundle:14]: outcome=frailty; directness=indirect; tier=B2; direction=negative; claims=50.
- Massamba 2026 [bundle:15]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=48.
- Borghini 2026 [bundle:17]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=42.
- Kalstad 2019 [bundle:53]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=41.
- Kezer 2024 [bundle:21]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=37.
- Ismail 2025 [bundle:23]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=35.
- Rodrigues 2024 [bundle:24]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=35.
- Shellard 2026 [bundle:22]: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=unclear; claims=35.
- Nanda 2025 [bundle:27]: outcome=immune; directness=indirect; tier=B2; direction=null; claims=32.
- Liu 2025b [bundle:28]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=31.
- Gil-Korilis 2026 [bundle:29]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=28.
- Kim 2025 [bundle:30]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=24.
- Xiao 2026 [bundle:31]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=23.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 3 indirectness gap: Han 2023 [bundle:45] vs Ojeda-Rodriguez 2024 [bundle:10]; Ojeda-Rodriguez 2024 [bundle:10] (direct, A1) vs Han 2023 [bundle:45] (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Han 2023 [bundle:45] vs Opstad 2022 [bundle:16]; Opstad 2022 [bundle:16] (direct, A1) vs Han 2023 [bundle:45] (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wojcicki 2023 [bundle:6] vs Jaeger 2024 [bundle:5]; Jaeger 2024 [bundle:5] (direct, A1) vs Wojcicki 2023 [bundle:6] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wojcicki 2023 [bundle:6] vs Farhat 2025 [bundle:18]; Farhat 2025 [bundle:18] (direct, A1) vs Wojcicki 2023 [bundle:6] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wojcicki 2023 [bundle:6] vs Salvador 2016 [bundle:51]; Salvador 2016 [bundle:51] (direct, A1) vs Wojcicki 2023 [bundle:6] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wojcicki 2023 [bundle:6] vs Sindi 2017 [bundle:56]; Sindi 2017 [bundle:56] (direct, A1) vs Wojcicki 2023 [bundle:6] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wojcicki 2023 [bundle:6] vs Werner 2018 [bundle:50]; Werner 2018 [bundle:50] (direct, A1) vs Wojcicki 2023 [bundle:6] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wojcicki 2023 [bundle:6] vs Freitas-Simoes 2018 [bundle:52]; Freitas-Simoes 2018 [bundle:52] (direct, A1) vs Wojcicki 2023 [bundle:6] (indirect) on contextual other — direct vs indirect must be kept separate

## References

- **Chen 2026.** _Association between leukocyte telomere length and neurodegenerative diseases: a prospective cohort in the UK Biobank._ Journal of Neurology, 2026. DOI: 10.1007/s00415-025-13479-1 PMID: 41670794.
- **Young 2025.** _Role of telomere length and telomerase activity in accelerated cellular aging and major depressive disorder: a systematic review._ Molecular Psychiatry, 2025. DOI: 10.1038/s41380-025-03296-3 PMID: 41053437.
- **Sasmita 2025.** _Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis._ Exploration of Targeted Anti-tumor Therapy, 2025. DOI: 10.37349/etat.2025.1002289 PMID: 40061142.
- **Su 2025.** _Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis._ Cell Biology and Toxicology, 2025. DOI: 10.1007/s10565-025-10115-6 PMID: 41286474.
- **Jaeger 2024.** _A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study._ Nutrients, 2024. DOI: 10.3390/nu16172963 PMID: 39275278.
- **Wojcicki 2023.** _Shorter leukocyte telomere length protects against NAFLD progression in children._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-31149-y PMID: 37012261.
- **Yang 2025.** _Determinants of temporal change in telomere length and its associations with chronic complications and mortality in type 2 diabetes: the Fremantle diabetes study phase II._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02832-3 PMID: 40611236.
- **Xiao 2025.** _Plant-based diet and mortality in adults with cardiovascular-kidney-metabolic syndrome: evidence from NHANES with mediation by leukocyte telomere length._ Renal Failure, 2025. DOI: 10.1080/0886022X.2025.2586326 PMID: 41219149.
- **Sun 2026.** _The association of periodontitis with telomere length: a meta-analysis._ BMC Medical Genomics, 2026. DOI: 10.1186/s12920-026-02323-8 PMID: 41923055.
- **Ojeda-Rodriguez 2024.** _Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial._ Cardiovascular Diabetology, 2024. DOI: 10.1186/s12933-024-02175-5 PMID: 38493287.
- **Ribeiro 2021.** _Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study._ International Journal of Environmental Research and Public Health, 2021. DOI: 10.3390/ijerph182111274 PMID: 34769797.
- **Werner 2018.** _Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study._ European Heart Journal, 2018. DOI: 10.1093/eurheartj/ehy585 PMID: 30496493.
- **Pitkanen 2021.** _Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length—The Special Turku Coronary Risk Factor Intervention Project (STRIP)._ Nutrients, 2021. DOI: 10.3390/nu13020318 PMID: 33499376.
- **Salvador 2016.** _A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study._ Rejuvenation Research, 2016. DOI: 10.1089/rej.2015.1793 PMID: 26950204.
- **Hastings 2024.** _Effect of long‐term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis._ Aging Cell, 2024. DOI: 10.1111/acel.14149 PMID: 38504468.
- **Liu 2025a.** _Association between human herpesvirus 6 status and sarcopenia risk: a UK biobank cohort study with sex-specific patterns and telomere length modification._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1623291 PMID: 41041314.
- **Freitas-Simoes 2018.** _Walnut Consumption for Two Years and Leukocyte Telomere Attrition in Mediterranean Elders: Results of a Randomized Controlled Trial._ Nutrients, 2018. DOI: 10.3390/nu10121907 PMID: 30518050.
- **Massamba 2026.** _Telomere length dynamics in adults living with HIV: A systematic review._ BMC Infectious Diseases, 2026. DOI: 10.1186/s12879-026-13243-4 PMID: 42000997.
- **Opstad 2022.** _Selenium and Coenzyme Q 10 Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality—Sub-Study of a Randomized Clinical Trial._ Nutrients, 2022. DOI: 10.3390/nu14163346 PMID: 36014852.
- **Farhat 2025.** _Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial._ Nutrients, 2025. DOI: 10.3390/nu17182974 PMID: 41010500.
- **Borghini 2026.** _Combined physical and cognitive training enhances telomere length in mild cognitive impairment patients._ BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07380-3 PMID: 41913117.
- **Kalstad 2019.** _Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients._ BMC Geriatrics, 2019. DOI: 10.1186/s12877-019-1383-9 PMID: 31881852.
- **Wattanathorn 2025.** _An Anthocyanin-and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms262210911 PMID: 41303396.
- **Sanchez-Gonzalez 2024.** _Effects of Physical Exercise on Telomere Length in Healthy Adults: Systematic Review, Meta-Analysis, and Meta-Regression._ JMIR Public Health and Surveillance, 2024. DOI: 10.2196/46019 PMID: 38194261.
- **Kezer 2024.** _Impact of sociodemographic disparities on sarcopenia, telomere length, and mortality in patients with liver disease in the US population._ BMC Gastroenterology, 2024. DOI: 10.1186/s12876-024-03488-1 PMID: 39528945.
- **Rodrigues 2024.** _Exposing telomere length’s impact on malnutrition risk among older adults residing in the community: Insights from cross-sectional data analysis._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0308612 PMID: 39499700.
- **Ismail 2025.** _Exploring the association between depression and telomere length: A systematic review and meta-analysis._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-07076-5 PMID: 40595131.
- **Shellard 2026.** _Unsuppressed Viremia and Lower CD4 Count Associated With Faster Telomere Attrition in African Children With Perinatal Human Immunodeficiency Virus on Long-term Antiretroviral Therapy._ The Journal of Infectious Diseases, 2026. DOI: 10.1093/infdis/jiag060 PMID: 41655979.
- **Sindi 2020.** _Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2020. DOI: 10.1093/gerona/glaa279 PMID: 33175128.
- **Mackintosh 2021.** _TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis._ BMJ Open Respiratory Research, 2021. DOI: 10.1136/bmjresp-2021-001127 PMID: 34857525.
- **Nanda 2025.** _Chronic inflammation mediates the relationship between physical activity and telomere length._ GeroScience, 2025. DOI: 10.1007/s11357-025-01818-z PMID: 40762785.
- **Liu 2025b.** _Platelet-to-lymphocyte ratio and telomere length in older adults: An inverted U-shaped nonlinear relationship: A nationwide cohort study._ Medicine, 2025. DOI: 10.1097/MD.0000000000044188 PMID: 40958330.
- **Gil-Korilis 2026.** _Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort._ Molecular Medicine, 2026. DOI: 10.1186/s10020-026-01423-6 PMID: 41721457.
- **Canudas 2019.** _Pistachio consumption modulates DNA oxidation and genes related to telomere maintenance: a crossover randomized clinical trial._ The American Journal of Clinical Nutrition, 2019. DOI: 10.1093/ajcn/nqz048 PMID: 31051499.
- **Kim 2025.** _Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms._ Nutrients, 2025. DOI: 10.3390/nu17121983 PMID: 40573097.
- **Xiao 2026.** _Longer leukocyte telomere length increases the odds of premature rupture of membranes: a cross-sectional study based on UK Biobank._ Scientific Reports, 2026. DOI: 10.1038/s41598-026-46566-y PMID: 41922689.
- **Agirbasli 2022.** _Leukocyte telomere length as a compensatory mechanism in vitamin D metabolism._ PLoS ONE, 2022. DOI: 10.1371/journal.pone.0264337 PMID: 35202418.
- **Fachrucha 2026.** _Shortened Telomere Length as a Risk Factor for Idiopathic Pulmonary Fibrosis: A Meta-Analysis._ The Open Respiratory Medicine Journal, 2026. DOI: 10.2174/0118743064421488251017061020 PMID: 41728098.
- **Oaks 2020.** _Impact of a nutritional supplement during gestation and early childhood on child salivary cortisol, hair cortisol, and telomere length at 4–6 years of age: a follow-up of a randomized controlled trial._ Stress (Amsterdam, Netherlands), 2020. DOI: 10.1080/10253890.2020.1728528 PMID: 32063089.
- **Sarkar 2026.** _Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer._ Cancers, 2026. DOI: 10.3390/cancers18030490 PMID: 41681962.
- **Puhlmann 2019.** _Association of Short-term Change in Leukocyte Telomere Length With Cortical Thickness and Outcomes of Mental Training Among Healthy Adults._ JAMA Network Open, 2019. DOI: 10.1001/jamanetworkopen.2019.9687 PMID: 31553468.
- **Sun 2025.** _Exercise delays aging: evidence from telomeres and telomerase —a systematic review and meta-analysis of randomized controlled trials._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1627292 PMID: 40642293.
- **Tian 2025.** _Association of life’s essential 8 with leukocyte telomere length and mitochondrial DNA copy number: Findings from the population-based UK Biobank study._ The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100557 PMID: 40250166.
- **Hanley 2025.** _Shorter Telomeres and Faster Telomere Attrition in Individuals With Five Syndromic Forms of Intellectual Disability: A Systematic Review and Meta‐Analysis._ Journal of Intellectual Disability Research, 2025. DOI: 10.1111/jir.13244 PMID: 40274277.
- **Ryall 2025.** _A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf068 PMID: 40247641.
- **Rodriguez-Esparragon 2025.** _Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer’s Disease._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms262210866 PMID: 41303353.
- **Sindi 2017.** _Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial._ Journal of Alzheimer's Disease, 2017. DOI: 10.3233/JAD-170123 PMID: 28777749.
- **Franzoni 2022.** _Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial._ Trials, 2022. DOI: 10.1186/s13063-022-06257-1 PMID: 35410445.
- **Tunnicliffe 2025.** _Infection and telomere length: A systematic review._ PLOS One, 2025. DOI: 10.1371/journal.pone.0333107 PMID: 40986533.
- **Han 2023.** _Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults._ Aging (Albany NY), 2023. DOI: 10.18632/aging.204533 PMID: 36805537.
- **Chen 2025.** _Aristolochic Acid and Alternative Lengthening of Telomeres Mechanisms Underlie Liver Angiosarcoma Pathogenesis._ Liver Cancer, 2025. DOI: 10.1159/000549466 PMID: 41394772.
- **Shen 2026.** _The association of serum levels of vitamin D with leucocyte telomere length, as a marker of biological aging: A meta-analysis._ Medicine, 2026. DOI: 10.1097/MD.0000000000044487 PMID: 41650046.
- **Hu 2022.** _Reverse causal relationship between periodontitis and shortened telomere length: Bidirectional two-sample Mendelian random analysis._ Frontiers in Immunology, 2022. DOI: 10.3389/fimmu.2022.1057602 PMID: 36601105.
- **Vlasova 2026.** _Parental Age Effects on Offspring Telomere Length Across Vertebrates: A Meta‐Analysis._ Molecular Ecology, 2026. DOI: 10.1111/mec.70215 PMID: 41556533.
- **Gerede 2026.** _A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives._ Medical Sciences, 2026. DOI: 10.3390/medsci14010100 PMID: 41892815.
- **Sanchez-Gonzalez 2025.** _Effect of Physical Exercise on Telomere Length: Umbrella Review and Meta-Analysis._ JMIR Aging, 2025. DOI: 10.2196/64539 PMID: 39846264.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "dbc325ed-d409-4733-bca9-15f76dad07bf",
  "title": "Research Synthesis: Telomere Rates \u2014 full paper"
}